Advanced Medical Solutions Group has appointed Peter Allen as a non-executive director effective from 4 December.
He will then become non-executive chairman from 1 January, replacing Dr Don Evans, who will retire from the board on 31 December.
Allen, 57, has extensive experience in the healthcare industry, having held key senior positions in a number of companies, playing a significant role in their development. This includes five years as chairman and interim chief executive of ProStrakan Group; and three years as chairman of Proximagen Neurosciences.
He is currently non-executive chairman of LSE-listed Future and AIM-listed Clinigen, as well as privately-owned companies Chroma Therapeutics and ProStrakan Group, although he will be stepping down from the latter on 31 December. Allen is also a non-executive director of Mecom, Scancell and privately-owned Oxford Nanopore Technologies and is a qualified chartered accountant.
Dr Evans said “We are delighted to welcome Peter to the board, firstly as a non-executive director and then as my replacement at the beginning of next year. His significant experience of driving significant value creation at a number of healthcare companies, in both executive and non-executive roles, will be invaluable in the next stage of AMS’s growth.”